{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Molecular+Residual+Disease",
    "query": {
      "condition": "Molecular Residual Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Molecular+Residual+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T08:29:28.002Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06230185",
      "title": "CtDNA Based MRD Testing for NAC Monitoring in TNBC",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "Minimal Residual Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Personalis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 422,
      "start_date": "2023-11-09",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06230185"
    },
    {
      "nct_id": "NCT07069595",
      "title": "PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Residual Disease",
        "Triple Negative Breast Cancer (TNBC)",
        "Stage II/III"
      ],
      "interventions": [
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Circulating tumor DNA (ctDNA) testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2026-02-26",
      "completion_date": "2032-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07069595"
    },
    {
      "nct_id": "NCT07214532",
      "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Carcinoma, Ductal, Breast",
        "Receptors, Estrogen (for ER-positive Requirement)"
      ],
      "interventions": [
        {
          "name": "ctDNA-Guided Treatment Strategy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 725,
      "start_date": "2026-03-24",
      "completion_date": "2037-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07214532"
    },
    {
      "nct_id": "NCT06005818",
      "title": "Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-01",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005818"
    },
    {
      "nct_id": "NCT05221827",
      "title": "Clinical Performance Evaluation of the C2i-Test",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "C2i Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "C2i Genomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "22 Years to 100 Years"
      },
      "enrollment_count": 3,
      "start_date": "2022-02-24",
      "completion_date": "2022-07-27",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "Bloomfield, New Jersey",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05221827"
    },
    {
      "nct_id": "NCT07071961",
      "title": "Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Regorafenib",
        "High Risk Patients"
      ],
      "interventions": [
        {
          "name": "Regorafenib (CT)",
          "type": "DRUG"
        },
        {
          "name": "Lorigerlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2026-02-11",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07071961"
    },
    {
      "nct_id": "NCT06401421",
      "title": "EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ctDNA MRD test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Exact Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1800,
      "start_date": "2024-06-07",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 53,
      "location_summary": "Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06401421"
    },
    {
      "nct_id": "NCT06529822",
      "title": "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Gastroesophageal Adenocarcinoma",
        "Melanoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Synthetic long peptide personalized cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Signatera assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2025-03-20",
      "completion_date": "2034-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529822"
    },
    {
      "nct_id": "NCT07025785",
      "title": "Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Lymph Node Metastasis"
      ],
      "interventions": [
        {
          "name": "Circulating tumor DNA",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-08-22",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07025785"
    },
    {
      "nct_id": "NCT04362462",
      "title": "Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Triple-negative Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Texas Tech University Health Sciences Center, El Paso",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "86 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 86 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2019-03-05",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-07-24T08:29:28.002Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362462"
    }
  ]
}